Lantheus Buys Progenics To Combine Radiopharmaceuticals With Precision Diagnostics
Executive Summary
Lantheus says the all-stock drug-diagnostics deal brings together complementary portfolios of ultrasound and radiopharmaceutical diagnostics with oncology therapeutics.